SynthesisFrontiers in oncology2025
Resection of the primary tumor with or without liver resection reduces the risk of death in patients with liver metastatic gastroenteropancreatic neuroendocrine tumors: a systematic review and meta-analysis.
Synthesis in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) patients frequently present with liver metastases (LM) at diagnosis. The benefit of primary tumor resection (PTR) in this context remains controversial. This meta-analysis aimed to quantify the effect of PTR on survival in GEP-NETs patients with LM. Methods: We performed a systematic search of PubMed and Embase for studies that compared survival outcomes in GEP-NETs patients with LM who underwent PTR versus those who did not. Pooled effects are reported as hazard ratios (HR) with 95% confidence intervals (CI). We also conducted sensitivity analyses to evaluate the robustness of the findings. Results: Of 1525 screened articles, 11 studies met inclusion criteria, comprising 4185 patients who underwent resection. PTR was associated with improved overall survival compared with non-resection (HR = 0.48, 95% CI: 0.43-0.55). Sensitivity analyses, performed by sequentially excluding individual studies, did not materially change the result. Conclusion: PTR is associated with increased survival among GEP-NETs patients presenting with LM; however, decisions should be individualized based on patient and tumor characteristics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.